Overview

A Phase IIa, Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Presence of SENS-401 in the Perilymph

Status:
Not yet recruiting

Trial end date:
2023-07-01

Target enrollment:

Participant gender:

Summary

The aim of this study is to detect the presence of SENS-401 in the perilymph of participants undergoing cochlear implant surgery after 7 days of oral administration of SENS-401.

Phase:

Phase 2

Details

Lead Sponsor:

Sensorion

Treatments:

Azasetron